Form 4: Alkermes Director Frank Wilson Reports Equity Transactions
Statement of Changes in Beneficial Ownership
Director Frank Anders Wilson exercised stock options and received new equity grants in Alkermes plc.
Summary
- Director Frank Anders Wilson acquired 6,142 ordinary shares through the exercise of restricted stock units.
- 1,475 shares were withheld by the company at a price of $36.95 per share to cover tax obligations.
- The director was granted 11,538 non-qualified stock options with an exercise price of $36.98.
- The director received 5,409 restricted stock units as part of an equity award.
- Following these transactions, the director holds 35,751 ordinary shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director equity compensation.
Positives
- Director maintains a significant direct ownership stake of 35,751 shares.
- Equity grants align director interests with long-term shareholder value.
Negatives
- Tax withholding resulted in the disposal of 1,475 shares.
Risks
- Future share price volatility may impact the value of unvested stock options and restricted stock units.
Future Outlook
The newly granted equity awards vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual general meeting occurring at least 50 weeks after the grant.
Industry Context
StockSavvy.ai notes that routine equity compensation filings for directors are standard corporate governance practices in the biopharmaceutical sector, reflecting typical retention and incentive structures.
Comparison to Industry Standards
- The use of restricted stock units and stock options for director compensation is consistent with standard practices among mid-cap biopharmaceutical companies.
- Tax withholding upon vesting is a standard administrative procedure for equity-based compensation.
Stakeholder Impact
- Minimal impact on shareholders as these are standard equity compensation transactions.
Next Steps
- Vesting of the 11,538 stock options and 5,409 restricted stock units on or before May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Grant date for new stock options and restricted stock units. |
| 05/21/2026 | Transaction date for exercise of restricted stock units and tax withholding. |
| 05/22/2026 | Filing date of the Form 4. |
| 05/20/2036 | Expiration date for the newly granted stock options. |
Keywords
Alkermes, ALKS, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.